New cell therapy aims to prevent transplant complications in kids with blood cancer

NCT ID NCT07366801

Recruiting now Disease control Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 14 times

Summary

This study tests a new approach to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk or relapsed blood cancers who need a stem cell transplant from a half-matched donor. The method involves giving special regulatory T cells along with the stem cell graft to reduce the risk of GVHD while preserving the immune system's ability to fight infections. The study aims to see if this approach is safe and feasible, with a goal of lowering severe GVHD rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, RELAPSED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITING

Moscow, Russia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE LYMPHOBLASTIC LEUKEMIA, HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA, RELAPSE ACUTE MYELOID LEUKEMIA, HIGH RISK ACUTE MYELOID LEUKEMIA, RELAPSED